IDEXX Laboratories, Inc. $IDXX Shares Sold by Claro Advisors LLC

Claro Advisors LLC cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 494 shares of the company’s stock after selling 194 shares during the quarter. Claro Advisors LLC’s holdings in IDEXX Laboratories were worth $265,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after purchasing an additional 30 shares during the period. Ameritas Advisory Services LLC purchased a new position in IDEXX Laboratories in the second quarter valued at about $36,000. WPG Advisers LLC bought a new stake in shares of IDEXX Laboratories in the first quarter worth $37,000. Finally, Bank of Jackson Hole Trust raised its stake in shares of IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $713.74 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market cap of $57.10 billion, a price-to-earnings ratio of 59.43, a PEG ratio of 4.06 and a beta of 1.62. The stock has a 50-day moving average price of $644.05 and a 200 day moving average price of $576.13. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $2.80 EPS. IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IDXX shares. Piper Sandler restated a “neutral” rating and issued a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday. Morgan Stanley raised their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $730.50.

Insiders Place Their Bets

In related news, EVP Michael G. Erickson sold 406 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director owned 262 shares of the company’s stock, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,793 shares of company stock worth $2,467,430 in the last quarter. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.